VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LUNG
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LUNGPulmonx Corporation
$2.56$108M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLUNGCash Flow

Pulmonx Corporation (LUNG) Cash Flow Statement

8Y historyFree accessUpdated daily

Operating cash flow of -$3.2M in 2026Q3 and cumulative operating cash burn of roughly $82M across the analyzed quarters indicate persistent cash consumption, warranting investor attention to the trajectory of the $52.7M cash balance.

Income StatementBalance SheetCash FlowRatios

LUNG Cash Flow Statement

Annual statement

LUNG Cash Flow Statement

Pulmonx Corporation (LUNG) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-25.58M-32.45M-31.54M-37.61M-45.14M-41.43M-30.63M-20.77M-18.39M
Operating CF Margin %--35.85%-37.64%-54.77%-84.11%-85.57%-93.58%-63.71%-91.95%
Operating CF Growth %47.54%-2.88%16.15%16.67%-8.95%-35.24%-47.52%-12.89%-
Net Income-42.55M-54M-56.39M-60.84M-58.92M-48.66M-32.23M-20.7M-18.48M
Depreciation & Amortization1.29M1.05M1.49M1.55M1.51M867K483K365K270K
Stock-Based Compensation7.31M022.95M22.1M003.2M364K366K
Deferred Taxes-10K00049K-6K0746K936K
Other Non-Cash Items11.36M22.43M2.11M2.14M19.29M14.21M2.71M864K36K
Working Capital Changes-2.98M-1.93M-1.7M-2.56M-7.06M-7.84M-4.79M-2.4M-1.52M
Change in Receivables1.43M1.07M-1.31M-3.1M-2.19M-2.43M1.46M-2.52M-262K
Change in Inventory-1.44M-765K-229K918K-3.64M-6.46M-5.05M-2.61M-1.25M
Change in Payables-1.88M270K2.28M-345K247K87K592K524K-648K
Cash from Investing-31K30.48M17.48M-2.01M-4.22M-46.26M12.69M-14.23M200K
Capital Expenditures-31K-452K-1.45M-807K-1.32M-3.67M-911K-720K-316K
CapEx % of Revenue0.03%0.5%1.73%1.18%2.46%7.58%2.78%2.21%1.58%
Acquisitions000000013.51M16K
Investments---------
Other Investing0000000-13.51M16K
Cash from Financing1.73M903K1.36M21.4M2.47M4.5M234.83M45.62M12.11M
Debt Issued (Net)1.18M-100K-95K19.91M-87K032.99M6M12M
Equity Issued (Net)554K1M002.56M4.5M201.39M39.67M0
Dividends Paid000000000
Share Repurchases0000-27K-26K0-12K0
Other Financing001.46M1.49M00446K-52K114K
Net Change in Cash-23.86M-1.15M-12.62M-18.18M-46.74M-83.08M217.03M10.64M-5.93M
Free Cash Flow-25.61M-32.9M-32.98M-38.42M-46.45M-45.1M-31.54M-21.48M-18.71M
FCF Margin %-28.85%-36.35%-39.37%-55.94%-86.57%-93.15%-96.37%-65.92%-93.53%
FCF Growth %21.49%0.26%14.14%17.3%-3%-42.97%-46.82%-14.83%-
FCF per Share-0.59-0.81-0.84-1.01-1.25-1.25-0.88-0.61-0.90
FCF Conversion (FCF/Net Income)0.60x0.60x0.56x0.62x0.77x0.85x0.95x1.00x1.00x
Interest Paid003.48M2.98M003.06M1.4M1.36M
Taxes Paid00556K471K00259K196K226K

Key Metrics

Growth RegimeDecelerating
ProfitabilityWeak
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Cash Losses Track Accounting Losses

Based on Pulmonx's reported quarterly figures, operating cash flow of -$3.2M in 2026Q3 against net income of -$8.4M produced an OCF/NI ratio of 0.38, meaning cash burn is smaller than the accounting loss but still persistently negative across all ten quarters analyzed.

The conversion ratio has moved from 0.92 in 2025Q1 to 0.38 in 2026Q3, which suggests that non-cash add-backs such as stock-based compensation and depreciation are absorbing a growing share of the reported loss. Stock-based compensation of $3.6M in the latest quarter accounts for a meaningful portion of that gap, so the net loss alone understates the underlying cash consumption of the business. The improving ratio should not be read as an earnings quality improvement, since operations consumed cash in every period shown.

Free Cash Flow Deeply Negative Throughout

As reported in the financial statements, Pulmonx's free cash flow margin improved from -60.0% in 2025Q1 to -14.0% in 2026Q3, yet the company has not generated positive free cash flow in any of the ten quarters analyzed.

The margin improvement is substantial, but it appears driven by revenue growth and cost discipline rather than any structural shift toward cash generation. Capital expenditure remains under 2% of revenue, so the burn is almost entirely operating in nature. Investors should monitor whether the margin trend continues toward breakeven, since the current trajectory still implies reliance on external funding sources that are not detailed in the supplied data.

Working Capital Swings Mask Underlying Burn

Based on Pulmonx's reported figures, working capital changes swung from a $4.8M outflow in 2025Q1 to a $4.7M inflow in 2025Q2, indicating that the timing of receivables and payables is driving meaningful quarter-to-quarter volatility in operating cash flow.

These swings are large relative to the company's cash flow base and suggest that operating cash flow in any single quarter may not reflect the sustainable run rate. The pattern warrants further investigation into collection timing and inventory management, since a reversal of the recent inflow would likely widen the cash burn. Interpretation should rely on multi-quarter averages rather than individual periods.

Asset-Light Model Limits Reinvestment Needs

According to recent SEC filings, Pulmonx's capital expenditure has fallen from 2.3% of revenue in 2024Q2 to effectively zero in 2026Q3, reflecting an asset-light operating model with minimal physical reinvestment requirements.

Low capital intensity means the company's cash needs are driven by operating expenses rather than fixed asset investment, which is consistent with a device company that may rely on outsourced manufacturing and direct sales. Depreciation of $622K in 2026Q3 is not being matched by meaningful replacement spending, which may indicate a small asset base rather than an underinvestment concern. The primary cash question is therefore operating burn rather than reinvestment.

Cumulative Cash Burn Exceeds Reported Losses

Based on Pulmonx's reported figures, cumulative operating cash flow across the ten quarters analyzed totals roughly -$82M, reflecting sustained operating outflows partially offset by non-cash charges embedded in the reported net loss.

The cumulative cash burn is the most material signal in the dataset, as it shows operations consumed cash in every quarter without a single period of positive free cash flow. Stock-based compensation provides non-cash relief to the income statement, but it represents a real economic cost to shareholders through dilution. Investors should monitor the balance between cash on hand and the pace of continued burn to assess how long current resources can sustain operations.

Margin Recovery Could Narrow the Burn

Based on Pulmonx's reported figures, the free cash flow margin has improved by roughly 46 percentage points since 2025Q1, and if that trajectory continued, the company could approach breakeven, though the supplied data does not establish that outcome.

A counter-view is that the operating cash burn is narrowing faster than the loss-based metrics suggest, given that the FCF margin moved from -60.0% to -14.0% over the period shown. If revenue growth and gross margin stability persist, the burn could compress further and reduce funding pressure. This interpretation is inferential, however, because the supplied data covers only ten quarters and does not include management guidance or external financing details.

LUNG — Frequently Asked Questions

Quick answers to the most common questions about buying LUNG stock.

How much cash does Pulmonx Corporation (LUNG) generate from operations?

Pulmonx Corporation (LUNG) generated $-32.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Pulmonx Corporation's free cash flow?

Pulmonx Corporation (LUNG) reported negative free cash flow of $32.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Pulmonx Corporation's capital expenditure (CapEx)?

Pulmonx Corporation (LUNG) spent $0.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.